Katsouri, L., Lim, Y.M., Blondrath, K., et al. (2016) PPARγ-Coactivator-1α Gene Transfer Reduces Neuronal Loss and Amyloid-β generation by Reducing β-Secretase in an Alzheimer’s Disease Model. Proceedings of the National Academy of Sciences of the United States of America, 113, 12292-12297.
https://doi.org/10.1073/pnas.1606171113

has been cited by the following article:

• TITLE: Therapeutic Potential of FGF21 in Alzheimer’s Disease

  AUTHORS: Anbang Sun, Benke Xu, Xianwang Wang, Lian Liu, Yun He, Zongwen Wang, Yuncai Chen

  KEYWORDS: FGF21, Alzheimer’ Disease, Amyloid-β (Aβ), Oxidative Stress, Inflamma-tion, Insulin Resistance

  JOURNAL NAME: Yangtze Medicine, Vol.2 No.1, December 13, 2017

  ABSTRACT: Alzheimer’s disease (AD) is the most common form of dementia which mostly affects persons younger than 65 years old. Mounting findings showed that amyloid-β (Aβ) peptides, oxidative stress, neuroinflammation and insulin resistance may play central role in the pathogenesis of AD. There are very many methods to slow it through affecting these aforementioned factors. However, more efficient prevention of the progression of AD is still ambiguous. Fibroblast growth factor 21 (FGF21) is an endocrine hormone that is expressed by several organs. It increases insulin sensitivity and regulates lipid metabolism and energy homeostasis. Emerging evidence demonstrates that FGF21 has potential effects in the brain involving metabolic regulation, neuroprotection and cognition. Hence, we hypothesize that FGF21 may be a protective factor in AD by attenuating Aβ generation, inflammation, oxidative stress, and insulin resistance. Our hypothesis will shed new light on the understanding of pathogenesis of AD and help to find a new way to prevent the genesis and progress of AD.